A Clinical Study Comparing the Effectiveness and Safety of Amphotericin B and Azole Drugs in Treating Invasive Fungal Disease

What this Trial Is About

This research aims to evaluate the effectiveness and safety of two types of antifungal drugs, amphotericin B and azoles, in patients with invasive fungal disease. The study collects medical records, demographic details, and clinical data from patients treated at Sichuan Provincial Peoples Hospital between 2021 and 2024 to compare these treatments. The purpose is to better understand how these drugs perform in real clinical settings to inform future care. Patients receive treatment with either polyene antifungal drugs, such as amphotericin B or its cholesteryl sulphate complex, or azole antifungal drugs, including triazoles or imidazoles. The dosage and length of treatment for both drug types are determined by clinicians based on clinical practice. The study is observational, recording outcomes as patients undergo their prescribed treatments. Participants contribute by allowing access to their medical records and clinical data for analysis. Researchers assess the clinical success rate at the end of treatment and up to one year afterward. Safety is monitored during treatment, at day 14, and at day 28 after treatment starts. The study does not involve additional interventions or procedures, focusing on data collection and evaluation over several months.

Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease